PISETSKY MICHAEL A. sold $57K of SIBN

Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.

SI-BONE (SIBN) received FDA 510(k) clearance for the iFuse Granite Onyx System, expanding its compromised bone solutions beyond the pelvis. The device targets spinal fusion issues in low-density bone, addressing a 27% loosening risk. The company aims to broaden its market and improve patient outcomes.

SI-Bone Inc (SIBN) shares rose 2.8% after receiving FDA 510(k) clearance for its iFuse Granite Onyx System, its first product for spinal fusion outside the pelvis. The system aims to address screw loosening in spinal fusions. CEO Laura Francis noted it is the company's third breakthrough device designation.

SI-BONE, Inc. (SIBN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance Delivered ~15% WW revenue growth and ~178% increase in adjusted EBITDA ~19% increase in U.S. physician base Second Quarter 2026 Financial Highlights (all comparisons are to t

INGRAM ORRIN H II purchased 29,081 shares of FB Financial Corp (FBK) at an average of $52.88 ($52.68–$53.11, $1.54M total) across 2 trades on 2026-10-20.

KAMFAR RAMIN purchased 271,555 indirectly-held shares of Bluerock Private Real Estate Fund (BPRE) at an average of $12.32 ($12.25–$12.43, $3.35M total) across 3 trades over 2026-10-19 to 2026-10-21.